Literature DB >> 6086640

Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase.

P A Furman, M H St Clair, T Spector.   

Abstract

The triphosphate form of 9-[(2-hydroxyethoxy)-methyl]guanine (acyclovir), ACVTP, inactivates the herpes simplex virus type 1 DNA polymerase. ACVTP does not innately inactivate resting polymerase, but becomes an inactivator only while being processed as an alternative substrate. Pseudo first-order rates of inactivation were measured at varying concentrations of ACVTP and fixed concentrations of the natural substrate, deoxyguanosine triphosphate. These studies indicated that a reversible enzyme-ACVTP (Michaelis-type) complex is formed at the active site prior to inactivation. The formation of this complex was competitively retarded by deoxyguanosine triphosphate. An apparent dissociation constant (KD) of 3.6 +/- 0.2 (S.D.) nM was determined for ACVTP from this reversible complex. A second method for the estimation of the KD which used the extrapolated initial velocities produced a value of 5.9 +/- 0.4 (S.D.) nM. The rate of conversion of the reversible complex to the inactivated complex, at saturating ACVTP, was calculated to be 0.24 min-1. No reactivation of enzyme activity was detected following isolation of the inactivated complex by rapid desalting on Sephadex G-25. Under these conditions, an overall reactivation rate of 1.5 X 10(-5) min-1 could have been easily detected. Therefore, the overall inhibition constant must have been less than 3 pM. In contrast, when host DNA polymerase alpha was incubated with 14 microM ACVTP, only 60% inhibition of enzyme activity was observed, but inactivation was not detected. These data indicate that ACVTP functions as a suicide inactivator of the herpes simplex virus type 1 DNA polymerase, and is only a weak reversible inhibitor of DNA polymerase alpha.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086640

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

Review 1.  Resistance of herpesviruses to antiviral drugs.

Authors:  P A Chatis; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

2.  Nobel lecture in physiology or medicine--1988. The purine path to chemotherapy.

Authors:  G B Elion
Journal:  In Vitro Cell Dev Biol       Date:  1989-04

3.  Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.

Authors:  M N Ellis; P M Keller; J A Fyfe; J L Martin; J F Rooney; S E Straus; S N Lehrman; D W Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

Review 4.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

5.  Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.

Authors:  Egor P Tchesnokov; Aleksandr Obikhod; Raymond F Schinazi; Matthias Götte
Journal:  J Biol Chem       Date:  2009-07-21       Impact factor: 5.157

6.  Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus.

Authors:  E M Swierkosz; D R Scholl; J L Brown; J D Jollick; C A Gleaves
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

7.  Reduced in vivo mutagenesis by mutant herpes simplex DNA polymerase involves improved nucleotide selection.

Authors:  J D Hall; P A Furman; M H St Clair; C W Knopf
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

8.  Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction.

Authors:  R Fernandez-Larsson; K O'Connell; E Koumans; J L Patterson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

9.  Regulation of herpes simplex virus thymidine kinase in cells treated with a synergistic antiviral combination of alpha interferon and acyclovir.

Authors:  J L Taylor; P Tom; J Guy; R M Selvarajan; W J O'Brien
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

10.  Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study.

Authors:  H B Hoh; C Hurley; C Claoue; M Viswalingham; D L Easty; P Goldschmidt; L M Collum
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.